FDA inspections are a critical part of ensuring that products in the pharmaceutical, medical, and food industries meet the necessary safety standards. Conner N. Mann, a Consumer Safety Officer with the FDA, has been instrumental in carrying out these inspections. His reports and insights play a vital role in helping manufacturers remain compliant with the FDA’s rigorous standards.

This blog will explore his inspection history in detail, highlighting recurring issues and standout observations. It will also examine key trends from his reports and explain how manufacturers can use these insights to improve compliance and quality control.

The Role of FDA Inspectors

FDA inspectors like Conner Mann are responsible for evaluating whether manufacturers are complying with regulations set to protect public health. During an FDA inspection, various factors are examined, including the company’s adherence to Good Manufacturing Practices (GMP), quality control systems, and documentation procedures.

Inspectors are particularly focused on ensuring that products are safe for consumers and that manufacturers are following the correct procedures for product testing, labeling, and reporting. A typical FDA inspection involves reviewing a company’s manufacturing processes, laboratory practices, product handling, and overall facility conditions.

Inspectors also verify whether companies are addressing previous compliance issues. If violations are found, FDA investigators issue Form 483 reports to notify the company of deficiencies that must be corrected.

Conner Mann’s Inspection History

Conner Mann has conducted 12 inspections in his career, with a total of 9 Form 483s issued. His inspections span a variety of industries, with a focus on drug manufacturing and medical products. These inspections provide valuable insights into recurring compliance issues that manufacturers can address before an inspection takes place.

Some key figures from his inspection history include:

  • Longest Inspection: 30 days
  • Shortest Inspection: 1 day
  • Average Length of Inspection: 7.7 days
  • Total Form 483s Issued: 9
  • Warning Letters Issued: 1

Mann’s inspections span locations both in the United States and internationally, including companies in India. Recent inspections have been carried out for companies like Paradox Inc., Plastikon Healthcare LLC, and Lupin Limited, among others. These inspections highlight key areas of focus, from manufacturing practices to labeling compliance.

Recent Inspections and Trends in Compliance

To understand the current direction of FDA inspections, it’s useful to look at some of the sites inspected by Conner Mann in 2023 and 2024. His inspection history highlights key regulatory focus areas and geographic trends.

2024 Inspections

In 2024, Mann primarily inspected companies in the United States, with a consistent focus on core regulatory issues such as manufacturing quality, data integrity, and labeling accuracy.

  • Paradox Inc (Saint Joseph, MO 11 Oct 2024)
  • Plastikon Healthcare LLC (Lawrence, KS 30 Apr 2024)
  • ILMO Products Company (Jacksonville, IL 28 Mar 2024)
  • Centaur Inc (Olathe, KS 01 Feb 2024)

2023 Inspections

Mann’s 2023 inspections included both U.S. companies and international manufacturers, especially in India, underscoring the FDA’s global oversight.

  • Aura Cacia (Urbana, IL 01 Dec 2023)
  • Cosmetic Solutions LLC (Boca Raton, FL 22 Sep 2023)
  • Lupin Limited (Unit II) (Mandideep, India 11 Aug 2023)
  • Solara Active Pharma Sciences Ltd (Cuddalore, India 04 Aug 2023)
  • University of Iowa Pharmaceuticals (UIP) (Iowa City, IA 22 Jun 2023)
  • Apollo Care, LLC (Columbia, MO 05 Apr 2023)

Key Issues in Conner Mann’s Inspections

Conner Mann’s inspection reports highlight several critical issues that manufacturers must address to stay compliant with FDA standards. Some of the most frequent issues observed during his inspections include:

  • Data Backup and Security Failures

One of the significant issues found during Mann’s inspections is the failure to maintain secure backup files for data entered into computer systems. Specifically, some manufacturers were unable to demonstrate that electronic raw data was protected from alterations or loss.

In the pharmaceutical industry, where data integrity is essential, ensuring that systems are in place to safeguard this information is critical to passing an FDA inspection.

  • Labeling and Control Deficiencies

Another key issue identified in Conner Mann’s inspections is the inadequate control over labeling for drug products. Manufacturers were found to lack proper procedures for the issuance, use, and accountability of labels. This issue is particularly concerning for medical gas products.

The failure to manage labeling effectively can lead to significant risks of non-compliance. In many cases, this can result in Form 483s being issued by regulatory authorities, signaling violations that need to be addressed.

  • Unresolved Discrepancies in Production

In multiple cases, Mann’s inspections revealed that manufacturers failed to investigate discrepancies in product batches. When a product or component fails to meet specifications, it’s essential to initiate an investigation and correct the issue promptly.

A failure to do so can not only lead to non-compliance but can also compromise consumer safety.

  • Deficient Component Testing

Mann’s reports also highlighted deficiencies in drug product component testing. Specifically, some manufacturers failed to perform microbiological testing for over-the-counter (OTC) drug products.

This oversight can result in significant health risks if contaminants are not detected early in the production process.

How Manufacturers Can Benefit from Conner Mann’s Reports?

By reviewing Conner Mann’s inspection findings, manufacturers can take a proactive approach to ensure compliance. Some key benefits include:

  • Identifying Potential Weaknesses: By analyzing common issues identified in Mann’s inspections, manufacturers can address these weaknesses before an official FDA inspection. This can significantly reduce the risk of receiving Form 483s or warning letters.
  • Improving Compliance Procedures: Regularly reviewing inspection reports can help companies update their internal processes, such as improving data backup procedures, tightening labeling controls, and ensuring thorough component testing.
  • Aligning with FDA Priorities: By staying informed about the trends observed in Mann’s inspections, manufacturers can better align their operations with FDA expectations. This allows companies to focus on the areas most likely to be scrutinized during inspections.

Conclusion

Conner Mann’s inspection history provides critical insights into the most common compliance challenges faced by manufacturers. By understanding his reports and the key trends in FDA inspections, companies can prepare more effectively and minimize the risk of regulatory violations.

Intelligence platforms like Atlas Compliance can provide valuable data and insights for organizations looking to stay ahead of regulatory requirements and streamline their compliance processes. With Atlas Compliance, manufacturers can track inspection trends, monitor potential risks, and ensure they are always inspection-ready.

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media